Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed No phase listed Observational

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

NCT00331331
View directory record Official record
Conditions
Uveitis, Vasculitis, Ocular Inflammatory Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

NCT01863953
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902
View directory record Official record
Conditions
Glaucoma
Interventions
BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Glendale, California • Newport Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

NCT00347594
View directory record Official record
Conditions
Healthy
Interventions
Next Generation Diagnostic Instrument (NGDI), Zyoptix Diagnostic Workstation (ZDW)
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
21 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145
View directory record Official record
Conditions
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 21, 2026, 8:58 PM EDT
Withdrawn Not applicable Interventional

Assuring Ophthalmologic Follow up

NCT04959422
View directory record Official record
Conditions
Vision Screening, Amblyopia
Interventions
Active scheduling
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
2 Years to 6 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Not applicable Interventional Results available

Electric Stimulation of the Eye to Improve Vision After Trauma

NCT02019927
View directory record Official record
Conditions
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
Interventions
Transcorneal Electrical Stimulation, Sham
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 8:58 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

NCT05045703
View directory record Official record
Conditions
Choroideremia
Interventions
Vitamin A palmitate
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
15 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

NCT01430754
View directory record Official record
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interactive Study to Increase Glaucoma Adherence to Treatment

NCT00794170
View directory record Official record
Conditions
Glaucoma
Interventions
Telephone and Print based intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Not applicable Interventional Results available

Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens

NCT01484054
View directory record Official record
Conditions
Refractive Ametropia
Interventions
etafilcon A with print and PVP for dark eyes (EAPVPDE), etafilcon A control lens (EADE)
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Bloomfield, Connecticut • Tallahassee, Florida • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

NCT00471731
View directory record Official record
Conditions
Turner Syndrome, Ovarian Failure, Premature, Sex Chromosome Aberrations, Menopause, Perimenopause
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572
View directory record Official record
Conditions
Ocular Melanoma, Uveal Melanoma
Interventions
Melphalan/HDS
Combination Product
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Tucson, Arizona • Palo Alto, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

NCT01841437
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
iStent
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Chico, California • Huntington Beach, California • Napa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 21, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care

NCT04994457
View directory record Official record
Conditions
Glaucoma
Interventions
Virtual Reality Visual Field, Standard Automated Perimetry
Device · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 90 Years
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

Eye Muscle Surgery to Treat Congenital Nystagmus

NCT00001866
View directory record Official record
Conditions
Nystagmus
Interventions
horizontal muscles of the eye will be cut and then reattached in the same position
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

NCT04708951
View directory record Official record
Conditions
Adenoma, Colorectal Cancer
Interventions
ENDOCUFF VISION® device, G-EYE® colonoscope
Device
Lead sponsor
Dr. Horst Schmidt Klinik GmbH
Industry
Eligibility
Not listed
Enrollment
970 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 21, 2026, 8:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Visual Perception in Schizophrenia

NCT06911931
View directory record Official record
Conditions
Schizophrenia Disorders, Bipolar Disorder, Schizo Affective Disorder
Interventions
EEG measure of visual processing
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

NCT00931801
View directory record Official record
Conditions
HIV
Interventions
atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

Improving Functional Health Literacy in Older Veterans

NCT00038337
View directory record Official record
Conditions
Visual And Cognitive Disability
Interventions
Health Literacy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 21, 2026, 8:58 PM EDT